Lung Cancer Diagnostic Test Market is estimated to be US$ 4.07 billion by 2030 with a CAGR of 7.50% during the forecast period


 Lung cancer starts in the lungs and can spread to the lymph nodes or other body organs, including the brain. Cancer that has progressed to other organs can potentially spread to the lungs. Metastases are the spread of cancer cells from one organ to another. Small cell and non-small cell lung tumors are the two most common kinds of lung cancer. These kinds of lung cancer grow and respond to treatment in different ways. Non-small cell lung cancer is more prevalent than small cell lung cancer, according to the American Cancer Society. Lung cancer symptoms range from person to person. Symptoms of the lungs affect some persons.

Region Analysis:

North America dominates the lung cancer diagnostics market, due to rising incidence of lung cancer and the ageing population in the particular region. North America is regarded as the largest regional market with the highest market share due to increased market invasion rates of technologically advanced products, rising patient awareness, and rising smoking prevalence levels in the region are all factors contributing to the region's greatest market share. Due to increased use of lung cancer diagnostics and rising tobacco smoking population in the region, Asia-Pacific (APAC) is predicted to have considerable growth over the projection period. 

Key Development:

  • AnPac Bio-Medical Science Co., Ltd, a biotechnology company focused on early cancer screening and detection with operations in China and the United States, announced on January 25, 2021, that China's medical product regulatory authority, the National Medical Products Administration, had approved AnPac Bio to begin registration testing of its Class III lung cancer auxiliary diagnosis medical device at a designated medical device testing laboratory, which is a sign of progress.
  • Amgen established significant partnerships with renowned diagnostic companies Guardant Health, Inc. and QIAGEN N.V. in January 2020 to develop blood and tissue-based companion diagnostics (CDx) for the investigational cancer therapy AMG 510, respectively. AMG 510 is the first KRASG12C inhibitor to make it to the clinic, where it will be studied in the treatment of a variety of tumour types. In human cancer, KRAS G12C is one of the most frequently mutated oncogenes. The CDx tests for non-small cell lung cancer will be the focus of the agreements with both firms at first (NSCLC).

Before purchasing this report, request a sample or make an inquiry by clicking the following link:

https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/4863

Segmentation:

The Global Lung Cancer Diagnostic Test Market accounted for US$ 1.98 billion in 2020 and is estimated to be US$ 4.07 billion by 2030 and is anticipated to register a CAGR of 7.50%. The Global Lung Cancer Diagnostic Test Market is segmented by Test Type, Cancer Type, End-Use Industry and Region.

  • By Test Type, the Global Lung Cancer Diagnostic Test Market is segmented into Biomarkers Test (EGFR Mutation Test, KRAS Mutation Test, ALK Test, HER2 Test, Others), Imaging Test ( Computed Tomography (CT) scan, Positron Emission Tomography (PET) scan, Chest X-Ray, Others), Biopsy (Needle Biopsy, Bronchoscopy Biopsy, Open Biopsy, Others.
  • By Cancer Type, the Global Lung Cancer Diagnostic Test Market is classified into Non-small cell lung cancer and Small Cell Lung Cancer.
  • By End-Use Industry, the Global Lung Cancer Diagnostic Test Market is classified into Hospital Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes and Others.
  • By region, the Global Lung Cancer Diagnostic Test Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Competitive Analysis:                                                                                                 

The key players operating in the Global Lung Cancer Diagnostic Test Market includes Abbott, Illumina, Inc., Thermo Fischer Scientific, QIAGEN, Quest Diagnostics Incorporated, NeoGenomics, NanoString, Myriad Genetics Inc., F. Hoffmann-La Roche Ltd, Danaher, Agilent Technologies, Inc., AstraZeneca, Sanofi, and Janssen Pharmaceuticals, Inc.

Comments

Post a Comment

Popular posts from this blog

Osteoporosis Treatment Market is estimated to be US$ 17.68 billion by 2030 with a CAGR of 4.3% during the forecast period

Image
  The   Osteoporosis Treatment Market   accounted for US$ 11.60 billion in 2020 and is estimated to be US$ 17.68 billion by 2030 and is anticipated to register a CAGR of 4.3%. Osteoporosis is a condition in which body loses too much bone and there is an increase in bone weakness. The individual suffering from osteoporosis is more exposed to bone fractures. Hence, a proper treatment is required to cure and avoid the chances of complications. Osteoporosis, or thinning bones, can result in painful fractures. Risk factors for osteoporosis include aging, being female, low body weight, low sex hormones or menopause, smoking, and some medications. Prevention and treatment include calcium and vitamin D, exercise, and osteoporosis medications. The report “ Global Osteoporosis Treatment Market By Drugs Type (Selective Estrogen Receptor Modulators (SERMs), Rank Ligand (RANKL) Inhibitor, Calcitonin, Hormone Therapy, Parathyroid Hormone-Related Protein (PTHrP) Analog, and Bisphosphonates (Risedrona
Read more

Hand Sanitizers Market is estimated to be US$ 2.70 billion by 2030 with a CAGR of 7.50% during the forecast period

Image
  Hand Sanitizers Market  accounted for US$ 1.31 billion in 2020 and is estimated to be US$ 2.70 billion by 2030 and is anticipated to register a CAGR of 7.50%. Hand sanitizer is an antiseptic solution, also known as a hand disinfectant, hand antiseptic, hand rub. It is a liquid or gel containing alcohol use as an alternative to soap and water. It is used to clean the hands and kill infection-causing microorganisms. The main difference between washing hands with soap and hand sanitizer is soap work to remove all types of germs from hands, while sanitizer acts as killing germs present on the skin. It is an alcohol-based hand sanitizer work to reduce the number of germs but it is less effective in removing harmful chemicals, such as pesticides and heavy metals like lead. The report " Global Hand Sanitizers Market by Type (Gel, Foam, and Spray), By Application (Restaurant, Hospital, School, Household, and Office Building,), and By Region (North America, Europe, Asia Pacific, Latin Am
Read more

Sternal Closure Systems Market is estimated to be US$ 3.79 Billion by 2020 with a CAGR of 5.6% during the forecast period 2030

Image
  Sternal Closure Systems   Market  accounted for US$ 2.3 million in 2020 and is estimated to be US$ 3.79 billion by 2030 and is anticipated to register a CAGR of 5.6%.        The Sternal Closure Systems are used in bilateral thoracosternotomy, median sternotomy and hemisternotomy. Median sternotomy has become popular in early 1960s and remains gold standard approach in cardiac procedures. Sternal Closure Systems are used in stabilization and fixation of fractures at anterior part of chest wall. Change in lifestyle, lack of exercise and unhealthy diet has become common cause of cardiovascular diseases. Newly developed technology in medical field in metropolitan cities has given rise to heart surgeries which has boosts the Sternal Closure Systems Market. As cardiac surgeries had become routine surgery, it is determined that annually around one million heart surgeries are performed worldwide. Rate of coronary heart diseases are high in United States of America. According to data publishe
Read more